MP53-18 ASSOCIATION BETWEEN A 17-GENE GENOMIC PROSTATE SCORE AND MULTI-PARAMETRIC PROSTATE MRI IN MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER (PCA)

Abstract

Listen

Translate article

You have accessJournal of UrologyProstate Cancer: Staging I1 Apr 2015MP53-18 ASSOCIATION BETWEEN A 17-GENE GENOMIC PROSTATE SCORE AND MULTI-PARAMETRIC PROSTATE MRI IN MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER (PCA) Michael Leapman, Antonio Westphalen, Niloufar Ameli, Jeffrey Lawrence, Phillip Febbo, Matthew Cooperberg, and Peter Carroll Michael LeapmanMichael Leapman More articles by this author , Antonio WestphalenAntonio Westphalen More articles by this author , Niloufar AmeliNiloufar Ameli More articles by this author , Jeffrey LawrenceJeffrey Lawrence More articles by this author , Phillip FebboPhillip Febbo More articles by this author , Matthew CooperbergMatthew Cooperberg More articles by this author , and Peter CarrollPeter Carroll More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1712AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES A biopsy-based RT-PCR assay (Oncotype DX® Prostate Assay) providing a Genomic Prostate Score (GPS) as a measure of tumor aggressiveness and multi-parametric prostate MRI (mpMRI) are both clinically utilized predictors of adverse pathology at prostatectomy. These tests have not been directly compared and it remains to be determined whether they provide independent information. METHODS We evaluated the association between GPS results (scale 0-100) and baseline endorectal mpMRI in men with clinically localized PCa. MR studies were reviewed to a five-tier scale of increasing suspicion of malignancy. Mean apparent diffusion coefficient (ADC) was calculated from a single dominant lesion. Mean rank of the GPS (0-100) and GPS-predicted likelihood of favorable pathology among MRI strata were compared with the Kruskal-Wallis test. Regression analysis was performed between mean ADC and scaled GPS within CAPRA risk groups. RESULTS Of 332 patients who received GPS testing at a single institution, 94 were identified with low (n=59) and intermediate (n=35) CAPRA risk prostate cancer who received mpMRI within a two-year interval of prostate biopsy. A broad distribution of GPS was observed across categories defined by mpMRI criteria. Among intermediate risk patients both GPS and the GPS-predicted likelihood of favorable pathology were associated with MR score (p=0.01 and p<0.01, respectively). For low risk patients, neither GPS nor likelihood of favorable pathology were significantly different across MR findings (p=0.12 and p=0.21, respectively). Mean ADC was not significantly associated with GPS or likelihood of favorable pathology for either low (p=0.24) or intermediate (p=0.91) risk categories. CONCLUSIONS While a broad distribution of GPS was observed across mpMRI criteria, increasing GPS was associated with highly suspicious MRI findings in men with intermediate risk PCa. No significant associations were observed between MRI categories and either GPS or likelihood of adverse pathology in low risk patients. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e642-e643 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael Leapman More articles by this author Antonio Westphalen More articles by this author Niloufar Ameli More articles by this author Jeffrey Lawrence More articles by this author Phillip Febbo More articles by this author Matthew Cooperberg More articles by this author Peter Carroll More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...